Treatment of Venous Thromboembolism in Cancer Patients

 

 Buy Article Permissions and Reprints

ABSTRACT

Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Its management remains challenging because patients with a cancer-associated thrombosis are at higher risk of recurrent VTE than are noncancer subjects with thrombosis and also have a greater risk for anticoagulant-associated bleeding complications while receiving therapy to prevent recurrent VTE. Recently, anticoagulant strategies based on the administration of low-molecular-weight heparin (LMWH) rather than vitamin K antagonists for up to 6 days to prevent recurrent VTE have been evaluated. These studies indicate that LMWH is associated with a lower rate for recurrent VTE and similar rates of bleeding when compared with oral anticoagulant therapy. Chronic exposure to LMWH may also prolong survival of cancer patients.

REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens.  Clinique Medicale de l'Hotel-Dieu de Pais. 1865;  3 654-712
  PubMedGoogle Scholar
• 2 Prandoni P, Lensing A W, Piccioli A et al.. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood. 2002;  100 3484-3488
  CrossrefPubMedGoogle Scholar
• 3 Hutten B A, Prins M H, Gent M, Ginsberg J, Tijssen J G, Buller H R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.  , [see comment] J Clin Oncol. 2000;  18 3078-3083
  PubMedGoogle Scholar
• 4 Petralia G, Kakkar A K. Antithrombotic therapy with low molecular weight heparin in cancer patients.  Eur J Med Res. 2004;  9 119-124
  PubMedGoogle Scholar
• 5 Buller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3 Suppl) 401S-428S
  CrossrefPubMedGoogle Scholar
• 6 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  (3 Suppl) 188S-203S
  CrossrefPubMedGoogle Scholar
• 7 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
  CrossrefPubMedGoogle Scholar
• 8 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.  Ann Intern Med. 1999;  130 800-809
  CrossrefPubMedGoogle Scholar
• 9 Dolovich L R, Ginsberg J S, Douketis J D, Holbrook A M, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.  Arch Intern Med. 2000;  160 181-188
  CrossrefPubMedGoogle Scholar
• 10 Shaughnessy S G, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.  Blood. 1995;  86 1368-1373
  PubMedGoogle Scholar
• 11 Muir J M, Hirsh J, Weitz J I, Andrew M, Young E, Shaughnessy S G. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.  Blood. 1997;  89 3236-3242
  PubMedGoogle Scholar
• 12 Levine M, Gent M, Hirsh J et al.. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  , [see comment] N Engl J Med. 1996;  334 677-681
  CrossrefPubMedGoogle Scholar
• 13 Koopman M M, Prandoni P, Piovella F et al.. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.  , [see comment] [Erratum appears in N Engl J Med 1997;337:1251] N Engl J Med. 1996;  334 682-687
  CrossrefPubMedGoogle Scholar
• 14 Hull R D, Raskob G E, Pineo G F et al.. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  , [see comment] N Engl J Med. 1992;  326 975-982
  CrossrefPubMedGoogle Scholar
• 15 Martins R, Colowick A, al Ewenstein B. Anticoagulation in cancer patients with venous thromboembolic disease.  Blood. 1997;  909(Suppl 1) 297A
  PubMedGoogle Scholar
• 16 Bona R D, Sivjee K Y, Hickey A D, Wallace D M, Wajcs S B. The efficacy and safety of oral anticoagulation in patients with cancer.  Thromb Haemost. 1995;  74 1055-1058
  PubMedGoogle Scholar
• 17 Meyer G, Marjanovic Z, Valcke J et al.. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.  , [see comment] Arch Intern Med. 2002;  162 1729-1735
  CrossrefPubMedGoogle Scholar
• 18 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  , [see comment] N Engl J Med. 2003;  349 146-153
  CrossrefPubMedGoogle Scholar
• 19 Deitcher S, Kessler C, Merli G, Rigas J, Lyons R, Cort S. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period.  , [abstract] J Thromb Haemost. 2003;  1(Suppl 1) OC194
  PubMedGoogle Scholar
• 20 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.  , [see comment] Am J Med. 1996;  100 269-277
  CrossrefPubMedGoogle Scholar
• 21 Hettiarachchi R J, Smorenburg S M, Ginsberg J, Levine M, Prins M H, Buller H R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.  Thromb Haemost. 1999;  82 947-952
  PubMedGoogle Scholar
• 22 Kakkar A KZ, Williamson R, Levine M, Low V, Lemoine N. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer.  Blood Coagul Fibrinolysis. 2002;  100 148A
  CrossrefPubMedGoogle Scholar
• 23 Kakkar A K, Levine M N, Kadziola Z et al.. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).  J Clin Oncol. 2004;  22 1944-1948
  CrossrefPubMedGoogle Scholar
• 24 Klerk C, Smorenburg S, Otten J, Büller H. Malignancy and low-molecular weight-heparin therapy: the MALT trial.  , [abstract] J Thromb Haemost. 2003;  1(Suppl 1) OC195
  PubMedGoogle Scholar
• 25 Lee A Y, Rickles F R, Julian J A et al.. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.  J Clin Oncol. 2005;  23 2123-2129
  Google Scholar
• 26 Lebeau B, Chastang C, Brechot J M et al.. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group.  Cancer. 1994;  74 38-45
  CrossrefPubMedGoogle Scholar
• 27 Altinbas M, Coskun H S, Er O et al.. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.  J Thromb Haemost. 2004;  2 1266-1271
  CrossrefPubMedGoogle Scholar

Dr. Gloria A Petralia

Centre for Surgical Science, Barts and The London Queen Mary's School of Medicine and Dentistry

Old Anatomy Building, Charterhouse Square, London EC1M 6BQ, United Kingdom

Email: petralia@tri-london.ac.uk